This polymorphism is also associated with more severe disease as determined by MELD score on the day of admission. Disclosures: The following people have nothing to disclose: Alison Jazwinski,

Amit Raina, Charles Gabbert, Shahid M. Malik, Michael O’Connell, David C. Whitcomb, Jaideep Behari Aim: to compare efficacy and safety of Budesonide and Pred-nisolone in treatment of acute alcoholic hepatitis (AAH). To determine predictors of non-response, predictors of short-time mortality. Methods: 35 patients with AAH were enrolled 3-deazaneplanocin A nmr in the prospective trial and randomised in 2 groups. Group 1: 15 patients (7 men, 8 women), average age 46,53±11,01. Median alcohol daily intake – 77 g., lower and upper quartiles – 55 and 96 g. Duration of alcohol intake – 13,41+8,55 years. Discriminant function (DF) average value was 65,22 (from 37,2 to 145,4). Group 2: 20 patients (16 men, 4 women), average age 46,5±11,89. Median alcohol daily intake – 70,55 g., lower and upper quartiles – 37 and 88 g. Duration of alcohol intake – 16,85+13,32 years. The average value of DF – 58,11 (from 32,1 to 121,7). Groups were comparable in key features. In group 1 Budesonide was prescribed 9 mg/daily per os. In group 2 – Prednisolone 40

mg/daily per os. Treatment duration was 28 Daporinad days. Response criteria – Lille model. Statistical analysis was performed using SPSS 17.0 statistical package (chi-squared, Mann-Whitney and Wilcoxon tests, Kaplan-Meier method and Cox regression model).

Results: Efficacy (p = 0,810) and short-term survival (p = 0,857) in budesonide group are equal to prednisolone group. In group 2 adverse events (infections, hepatorenal syndrome, hyper-glycemia, upper gastrointestinal bleeding and Cushing’s syndrome) were statistically more frequently than in group 1: 70% vs. 26,7% (p = 0,011). Hepatorenal syndrome occurred more frequently in group 2 (p = 0,033). Predictors of non-response are MELD score (p=0,009), ABIC score (p=0,011), hepatic encephalopathy level (p=0,035), total bilirubin level (p=0,016). Predictors of mortality are Lille score (p=0,018), serum glucose level (p=0,017), total bilirubin level at the 7th day of the therapy (p=0,030). There is a positive PD184352 (CI-1040) correlation between BMI and absence of therapy response (correlation coefficient 0,519 ) and short-time mortality (correlation coefficient 0,630). Conclusions: Short-time survival in budesonide group is equal to prednisolone group, so budesonide can be used in treatment of this disease. According to the data resulting from the study budesonide is the drug of choice in patients with concomitant infections, hepatorenal syndrome and glucose intolerance. Disclosures: The following people have nothing to disclose: Inna Komkova, Marina V. Maevskaya, Vladimir T.